Exhibit 99.1
Zymeworks to Present at Raymond James 41st Annual Institutional Investors Conference
Vancouver, Canada (February 24, 2020)– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Raymond James Institutional Investors Conference taking place March1-4, 2020 in Orlando, FL.
The Company’s presentation will be on Monday, March 2, 2020 at 2:15 p.m. ET.
Interested parties can access a live webcast of the presentation via a link from Zymeworks’ websiteat http://ir.zymeworks.com/events-and-presentations, which will also host a recorded replay available afterwards.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2 clinical development. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks’ proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit www.zymeworks.com.
Contacts:
Zymeworks Inc.
Investor Inquiries:
Ryan Dercho, Ph.D.
(604)678-1388
ir@zymeworks.com
Tiffany Tolmie
(604)678-1388
ir@zymeworks.com
Media Inquiries:
Kavita Shah, Ph.D.
(604)678-1388
info@zymeworks.com
